Engineered gut bacteria improve survival outcomes in colorectal cancer tumors

In a new study that combines synthetic biology with cancer immunotherapy, researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Central South University in China have developed an engineered strain of gut-homing bacteria that stimulates potent antitumor immune responses against colorectal cancer (CRC).

Antitumor immune responses refer to the actions taken by the body’s immune system to recognize, attack, and destroy cancer cells. It operates like the body’s internal surveillance system, spotting rogue cells (like tumor cells) and activating its defense forces to eliminate them.

Harnessing the immune system to fight cancer offers a powerful and precise approach to disease control. Unlike traditional treatments such as chemotherapy or radiation, which can harm healthy cells, immune responses can selectively target and destroy cancer cells with high specificity.

However, many tumors develop ways to suppress or evade the immune system, creating a hostile microenvironment that works to hide them from immune attack. Enhancing antitumor immune responses helps overcome this suppression and has been linked to improved treatment outcomes and longer survival rates.

Sign up for Blog Updates